Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAL0891 + Carboplatin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAL0891 | BAL-0891|BAL 0891 | MPS1 Inhibitor 27 PLK1 Inhibitor 18 | BAL0891 inhibits both TTK (MPS1) and PLK1, which potentially leads to disrupted cell cycle progression and decreased tumor cell proliferation (Cancer Res (2022) 82 (12_Supplement): 5645). | |
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05768932 | Phase I | BAL0891 + Carboplatin BAL0891 + Paclitaxel BAL0891 | BAL0891 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |